论文部分内容阅读
胺苯吖啶为抗肿瘤新药,由美国派德药厂研制推出。经临床验证,效果甚佳。尤其对顽固性、复发性白血病,缓解率较高。国外常将胺苯吖啶列为治疗成人急性非淋巴性细胞白血病的第二线治病方案。胺苯吖啶的主要适应症是治疗常规诱导缓解无效的成人急性白血病,其中又以对急性非淋类最为有效。使用方案为每五天为一疗程,每疗程总剂量为375～625mg/m~2,两疗程之间需间歇3～4周。通常使用剂量为75～125mg/(m~2a),连用5天,从小剂量开始75mg/(m~2a)。一但达到完成缓解则应改用维特剂
Benzene acridine for anti-tumor drugs, developed by the United States and Germany Pharmaceutical introduced. Clinical validation, the effect is very good. Especially for refractory, recurrent leukemia, remission rate higher. Often foreign amine benzene acridine as the treatment of adult acute non-lymphocytic leukemia second-line treatment program. The main indication for the administration of acamproside is the treatment of adult acute leukemias, which are routinely induced remission ineffective, which in turn are most effective against acute nongonphritis. The use of the program for every five days for a course of treatment, the total dose of each course of 375 ~ 625mg / m ~ 2, between the two courses need to intermittent 3 to 4 weeks. Commonly used dose of 75 ~ 125mg / (m ~ 2a), once every 5 days, starting from a small dose of 75mg / (m ~ 2a). Once the relief is achieved, the agent should be used instead